Study outcome won't sway company on eye drug

August 27, 2008 By KEVIN FREKING , Associated Press Writer

(AP) -- What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.



Content from The Associated Press expires 15 days after original publication date. For more information about The Associated Press, please visit www.ap.org .

Similar stories from PHYSorg:


Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration

created Oct 09, 2009 | popularity not rated yet | comments 0

New therapy for vasculitis will help patients avoid infertility and cancer

created Oct 18, 2009 | popularity not rated yet | comments 0

Discovery offers potential new pancreatic cancer treatment

created Nov 02, 2009 | popularity 3 / 5 (1) | comments 1

Study reports success in treating a rare retinal disorder

created Apr 13, 2009 | popularity not rated yet | comments 0

Diabetes drugs increase risk of heart failure, research shows

created Jul 27, 2007 | popularity 3.8 / 5 (5) | comments 0


print this article email this article download pdf blog this article bookmark this article     Stumble it Digg this share on Facebook retweet share on Reddit add to delicious
Rate this story - 5 /5 (10 votes)

Rank Filter

Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

  • Shirley - Aug 31, 2008
    • Rank: not rated yet
    In all of the discussions surrounding Lucentis vs. Avastin, nowhere is anybody talking about the inherent risk using a compounded medication. The reason we have the FDA-approval process is to provide an assurance that a drug has gone through rigorous testing for safety and efficacy and in the case of an injection like Lucentis, sterility is always of concern.

    Using compounded drugs because they are cheaper is NOT the reason a compounded drug should ever be used. Rather a compounded drug should be used only because there is no other commercially available option for the patient. If we want cheap, why not get rid of the FDA approval process? That%u2019s essentially what we are doing when we promote compounded drugs over FDA approved drugs because of costs.

    The only group benefitting from this move towards cheaper and not safer drugs is the pharmacy compounders who are successfully creating a %u2018second%u2019 tier pharmaceutical industry - one that is self-regulated and doesn%u2019t have to conform to any federal regulations regarding the safety, efficacy or sterility of their drugs.

    Physicians who choose to prescribe the cheaper unapproved drug must, in plain English, explain to their patients they have decided to administer them a drug that is NOT FDA-approved for safety, efficacy or sterility for WMD and why they are doing so.

    For patients on Medicare and other insurance, the FDA-approved drug, Lucentis, is covered, as it should be, and physicians place patients at unnecessary risk when using a compounded avastin instead. Recently, Britain%u2019s National Institute of Health and Clinical Excellence recommended Lucentis be available to U.K. residents.

    We should all be greatly concerned that our government, led by these physicians, is creating a precedent where insurers are being encouraged to NOT reimburse for an FDA-approved drug because a compounding pharmacy can make something cheaper, even though they cannot guarantee the safety, efficacy or sterility of every product they make.

    Headlines in 2007 from Oregon where three patients died from a 'mistake' made in a compounding pharmacy begs the question, "How do we justify increased risk using unapproved drugs to save money as being 'best for the patient?"

August 27, 2008 all stories

Comments: 1

5 /5 (10 votes)
  • Stumble this up

  • Digg this

  • share this

  • hide
  • Related Stories

  • Ethics guide for rural MDs
    created Nov 10, 2009 | popularity not rated yet | comments 0
  • The Medical Minute: Talk about prescriptions
    created Oct 28, 2009 | popularity not rated yet | comments 0
  • Identifying Molecules in Infrared Could Lead to New Medicines
    created Oct 27, 2009 | popularity not rated yet | comments 0
  • Why antidepressants don't work for so many
    created Oct 23, 2009 | popularity not rated yet | comments 0
  • Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration
    created Oct 09, 2009 | popularity not rated yet | comments 0



  • hide
  • Relevant PhysicsForums posts

Other News

FDA questions safety of alcoholic energy drinks

Medicine & Health / Health

created 20 hours ago | popularity 1 / 5 (1) | comments 5

(AP) -- The Food and Drug Administration is challenging makers of alcohol-infused energy drinks to prove their beverages are safe, citing complaints that the products can cause risky behavior and injury.


Study: Can meditation sharpen our attention?

Medicine & Health / Neuroscience

created 19 hours ago | popularity 3.7 / 5 (3) | comments 3

(PhysOrg.com) -- A new study at the University of Wisconsin-Madison suggests that people can train their minds to stay focused.


When preschoolers ask questions, they want explanations

Medicine & Health / Psychology & Psychiatry

created 18 hours ago | popularity 4 / 5 (2) | comments 2

Curiosity plays a big part in preschoolers' lives. A new study that explored why young children ask so many "why" questions concludes that children are motivated by a desire for explanation.


No need to fast for cholesterol test

Medicine & Health / Research

created 21 hours ago | popularity 5 / 5 (5) | comments 2

(PhysOrg.com) -- Patients do not need to fast before having their cholesterol tested, a major study has found.


'Cross-talk' mechanism contributes to colorectal cancer

Medicine & Health / Cancer

created 15 hours ago | popularity 5 / 5 (1) | comments 0

Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal ...